

Hidradenitis Suppurativa (HS)

Selected References:

- Althagafi H, et al. 2022. Effect of hidradenitis suppurativa on obstetric and neonatal outcomes. *J Matern Fetal Neonatal Med*; 35(25):8388-8393.
- Chellappan B, et al. 2022. Dermatologic Management of Hidradenitis Suppurativa and Impact on Pregnancy and Breastfeeding. *Cutis*; 109(3):160-162.
- Collier E, et al. 2020. Special considerations for women with hidradenitis suppurativa. *Int J Womens Dermatol*; 6(2):85-88.
- Fitzpatrick L, et al. 2022. Adverse pregnancy and maternal outcomes in women with hidradenitis suppurativa. *J Am Acad Dermatol*; 86(1):46-54.
- Li K, et al. 2024. Hidradenitis Suppurativa and Maternal and Offspring Outcomes. *JAMA Dermatol*. 160(12):1297-1303.
- Lotan P, et al. 2023. Association between Hidradenitis Suppurativa and Abnormalities in Semen Parameters and Sexual Function: A Pilot Study. *Acta Derm Venereol*; 103:adv11603.
- Lyons AB, et al. 2020. Evaluation of Hidradenitis Suppurativa Disease Course During Pregnancy and Postpartum. *JAMA Dermatol*; 156(6):681-685.
- Lyons AB, et al. 2020. Retrospective cohort study of pregnancy outcomes in hidradenitis suppurativa. *Br J Dermatol*; 183(5):945-947.
- Oumeish OY, Al-Fouzan AW. 2006. Miscellaneous diseases affected by pregnancy. *Clin Dermatol*; 24(2):113-7.
- Özbek L, et al. 2025. Hidradenitis Suppurativa Treatment During Pregnancy and Lactation: Navigating Challenges. *Int J Dermatol*; 64(7):1173-1185.
- Prens LM, et al. 2021. Hidradenitis suppurativa disease course during pregnancy and postpartum: a retrospective survey study. *Br J Dermatol*; 185(5):1072-1074.
- Sakya SM, et al. 2022. Outcomes of pregnancy and childbirth in women with hidradenitis suppurativa. *J Am Acad Dermatol*; 86(1):61-67.
- Seivright JR, et al. 2022. Impact of Pregnancy on Hidradenitis Suppurativa Disease Course: A Systematic Review and Meta-Analysis. *Dermatology*; 238(2):260-266.
- Tzur Bitan D, et al. 2021. The association between hidradenitis suppurativa and male and female infertility: A population-based study. *Australas J Dermatol*; 62(2):e223-e227.
- Vossen AR, et al. 2017. Menses and pregnancy affect symptoms in hidradenitis suppurativa: A cross-sectional study. *J Am Acad Dermatol*; 76(1):155-156.
- Walsh DP. 2025. Pregnancy Outcomes in Hidradenitis Suppurativa Patients. *AMIA Annu Symp Proc*; 2024:1169-1175.

Questions? Call 866.626.6847 | Text 855.999.3525 | Email or Chat at [MotherToBaby.org](https://www.MotherToBaby.org).

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, September 1, 2025.

Hidradenitis Suppurativa (HS)

Selected References:

- Abboud TK, et al. 1983. Lack of adverse neonatal neurobehavioral effects of lidocaine. *Anesth Analg*; 62:473-475.
- Abboud TK, et al. 1984. Continuous infusion epidural analgesia in parturients receiving bupivacaine, chloroprocaine, or lidocaine – maternal, fetal, and neonatal effects. *Anesth Analg*; 63:421-428.
- Actavis Pharma, Inc. 2019. Lidocaine and Prilocaine Cream Drug Label. Available at: <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1972d657-2d5a-4697-bba9-80caffc2f2d7>. Accessed 29 July 2025.
- Baradari AG, et al. 2017. Bolus administration of intravenous lidocaine reduces pain after an elective caesarean section: Findings from a randomised, double-blind, placebo-controlled trial. *J Obstet Gynaecol*. 37(5):566-570.
- da Cunha YGM et al. 2025. The Use of Different Local Anesthetics in Pregnant Women in Dentistry: A Systematic Review. *Curr Rev Clin Exp Pharmacol*. Apr 21. doi: 10.2174/0127724328349965250407082245. Online ahead of print.
- Demeulemeester V, et al. 2018. Transplacental lidocaine intoxication. *J Neonatal-Perinatal Med*; 11:439-441.
- Dryden RM, Lo MW. 2000. Breast milk lidocaine levels in tumescent liposuction. *Plast Reconstr Surg*; 105:2267-2268.
- Favero V, et al. 2021. Pregnancy and Dentistry: A Literature Review on Risk Management during Dental Surgical Procedures. *Dent J (Basel)*. 9(4):46.
- Fujinaga M, Mazze RI. 1986. Reproductive and teratogenic effects of lidocaine in Sprague-Dawley rats. *Anesthesiology*. 65:626-632.
- Heinonen OP, et al. 1977. *Birth Defects and Drugs in Pregnancy*. Publishing Sci Group, Littleton, MA.
- Kuhnert BR, et al. 1984. Effects of maternal epidural anesthesia on neonatal behavior. *Anesth Analg*; 63:301-308.
- Kuhnert BR, et al. 1986. Lidocaine disposition in mother, fetus, and neonate after spinal anesthesia. *Anesth Analg* 65:139-144.
- Lebedevs TH, et al. 1993. Excretion of lignocaine and its metabolite monoethylglycinexylidide in breast milk following its use in a dental procedure. A case report. *J Clin Periodontol* 20: 606-608.
- Li JE, et al. 2019. Cutaneous Surgery in Patients Who Are Pregnant or Breastfeeding. *Dermatol Clin*. 37(3):307-317.
- Murzaku EC, et al. 2021. Surgical management and practices in pregnancy and lactation: A survey of United States dermatologic surgeons. *J Am Acad Dermatol*. 84(4):1134-1136.
- Ortega D, et al. 1999. Excretion of lidocaine and bupivacaine in breast milk following epidural anesthesia for cesarean delivery. *Acta Anaesthesiol Scand*; 43:394-397.
- Silveira MPT, et al. 2020. Breastfeeding and risk classification of medications used during hospitalization for delivery: 2015 Pelotas Birth Cohort. *Rev Bras Epidemiol*. 23:e200026.
- Watson PD, Ott MA. 1982. Lidocaine and mepivacaine in cord blood. *Ped Pharm*; 2:341-348.

- Wikland, M., Evers, H., Jakobsson, A.-H., Sandqvist, U., & Sjöblom, P. (1990). The concentration of lidocaine in follicular fluid when used for paracervical block in a human IVF-ET programme. *Human Reproduction*, 5(8), 920-923
- Zeisler JA, et al. 1986. Lidocaine excretion in breast milk. *Drug Intell Clin Pharm*; 20:691-693.

Questions? Call 866.626.6847 | Text 855.999.3525 | Email or Chat at MotherToBaby.org.

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, September 1, 2025.

Hidradenitis Suppurativa (HS)

Selected References:

- Dentsply Pharmaceutical, Inc. 2021. Prilocaine injection drug label. Available at: <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=db23a56f-1e41-4843-9220-1b2e3059db41>. [Accessed 8/2025].
- Fougera & Co. 2024. Lidocaine and prilocaine cream drug label. Available at: <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=833cd52c-6470-49c4-937f-1393971f4db9>. [Accessed 8/2025].
- Erol S, et al. 2017. Transient methemoglobinemia in three neonates due to maternal pudendal anesthesia. *J Coll Physicians Surg Pak*. 27(12):783-784.
- Guay J. 2009. Methemoglobinemia related to local anesthetics: a summary of 242 episodes. *Anesth Analg*. 108(3):837-45.
- Kirschbaum M, et. al. 1991. [Fetal methemoglobinemia caused by prilocaine—is use of prilocaine for pudendal block still justified?]. *Geburtshilfe Frauenheilkd*. 51(3):228-30.
- Uslu S, Comert S. 2013. Transient neonatal methemoglobinemia caused by maternal pudendal anesthesia in delivery with prilocaine: report of two cases. *Minerva Pediatr*. 65(2):213-7.

Questions? Call 866.626.6847 | Text 855.999.3525 | Email or Chat at [MotherToBaby.org](https://www.MotherToBaby.org).

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, September 1, 2025.

Hidradenitis Suppurativa (HS)

Selected References:

- Gilboa SM, et al. 2009. National Birth Defects Prevention Study: Use of antihistamine medications during early pregnancy and isolated major malformations. *Birth Defects Res A Clin Mol Teratol* 85(2):137-150.
- Gilboa SM, et al. 2014. Antihistamines and birth defects: a systematic review of the literature. Expert opinion on drug safety. 13.12: 1667-98.
- Hansen Craig, et al. 2020. Use of antihistamine medications during early pregnancy and selected birth defects: The National Birth Defects Prevention Study, 1997–2011. ***Birth defects research***16: 1234-52.
- Ito S, et al. 1993. Prospective follow-up of adverse reactions in breast-fed infants exposed to maternal medication. *Am J Obstet Gynecol* 168:1393-9.
- Kallen B, Mottet I. 2003. Delivery outcome after the use of meclizine in early pregnancy. *Eur J Epidemiol*. 18:665-669.
- Katselou M, et al. 2018. A fully validated method for the simultaneous determination of 11 antihistamines in breast milk by gas chromatography-mass spectrometry. *Biomed Chromatogr* 32(8):e4260.
- Lenz W. 1966. Malformations caused by drugs in pregnancy. *Am J Dis Child* 112:99-106.
- Messinis IE, et al. 1985. Histamine H1 receptor participation in the control of prolactin secretion in postpartum. *J Endocrinol Investig* 8:143-6.
- Michaelis J, et al. 1983. Prospective study of suspected associations between certain drugs administered during early pregnancy and congenital malformations. *Teratology* 27:57-64.
- Mondillo C, et al. 2018. Potential negative effects of anti-histamines on male reproductive function. ***Reproduction***. 155.5: R221-7.

Questions? Call 866.626.6847 | Text 855.999.3525 | Email or Chat at [MotherToBaby.org](https://www.MotherToBaby.org).

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, September 1, 2025.

Hidradenitis Suppurativa (HS)

Selected References:

- Ceyhan ST, et al. 2010. Serum vitamin B12 and homocysteine levels in pregnant women with neural tube defect. *Gynecol Endocrinol*. 26(8):578-581.
- Dror DK, Allen LH. 2018. Vitamin B-12 in human milk: A systematic review. *Adv Nutr* 9:358s-66s.
- Duggan C, et al. 2014. Vitamin B-12 supplementation during pregnancy and early lactation increases maternal, breast milk, and infant measures of vitamin B-12 status. *J Nutr*. 144(5):758-764.
- Groenen PMW, et al. 2004. Marginal maternal vitamin B12 status increases the risk of offspring with spina bifida. *Am J Obstet Gynecol* 191(1):11-17.
- Hampel D, Allen LH. 2016. Analyzing B-vitamins in human milk: Methodological approaches. *Crit Rev Food Sci Nutr* 56:494-511.
- Lai JS, et al. 2019. Maternal plasma vitamin B12 concentrations during pregnancy and infant cognitive outcomes at 2 years of age. *Br J Nutr*. 121(11):1303-1312.
- Munger RG, et al. 2021. Maternal vitamin B12 status and risk of cleft lip and cleft palate birth defects in Tamil Nadu State, India. *Cleft Palate Craniofac J* 58(5):567-576.
- National Institute of Health Office of Dietary Supplements. 2024. Vitamin B12: Fact Sheet for Health Professionals. Available at: <https://ods.od.nih.gov/factsheets/VitaminB12-HealthProfessional/>. Accessed 6 Jun 2024.
- Nelen WL, et al. 2000. Hyperhomocysteinemia and recurrent early pregnancy loss: a meta-analysis. *Fertil Steril*. 74(6):1196-1199.
- Ray JG, Blom HJ. 2003. Vitamin B12 insufficiency and the risk of fetal neural tube defects. *QJM*. 96(4):289-295.
- Ray JG, et al. 2007. Vitamin B12 and the risk of neural tube defects in a folic-acid-fortified population. *Epidemiology* 18(3):362-366.
- Reznikoff-Etievant MF, et al. 2002. Low Vitamin B(12) level as a risk factor for very early recurrent abortion. *Eur J Obstet Gynecol Reprod Biol*. 104(2):156-159.
- Senousy SM, et al. 2018. Association between biomarkers of vitamin B12 status and the risk of neural tube defects. *J Obstet Gynaecol Res*. 44(10):1902-1908.
- Suarez L, et al. 2003. Maternal serum B12 levels and risk for neural tube defects in a Texas-Mexico border population. *Ann Epidemiol* 13(2):81-88.

- Van Rooij IALM, et al. 2003. Vitamin and homocysteine status of mothers and infants and the risk of nonsyndromic orofacial clefts. *Am J Obstet Gynecol* 189(4):1155-1160.
- Wilson A, et al. 1999. A common variant in methionine synthase reductase combined with low cobalamin (vitamin B12) increases risk for spina bifida. *Mol Genet Metab*. 67(4):317-323.
- Zhang T, et al. 2009. Maternal serum vitamin B12, folate and homocysteine and the risk of neural tube defects in the offspring in a high-risk area of China. *Public Health Nutr*. 12(5):680-686.

Questions? Call 866.626.6847 | Text 855.999.3525 | Email or Chat at [MotherToBaby.org](https://www.MotherToBaby.org).

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, September 1, 2025.